Uppsala, Sweden, November 20, 2024. The first participants in Dicot Pharma's Phase 2a clinical study have now been dosed. The company's drug candidate LIB-01 is being developed as a new first-line treatment for erectile dysfunction.
Dicot Pharma has recently started its Phase 2a clinical study with the potency drug candidate LIB-01. The purpose of the study is to evaluate the efficacy of LIB-01 in men with erectile dysfunction. The first participants in the study have now been dosed, at sites in Stockholm and Gothenburg. All participants will be dosed for three consecutive days and then followed for eight weeks to monitor efficacy and safety. Recruitment is ongoing throughout the clinical phase of the study.
"Now we are underway! The first participants have been dosed and the 2a-study is now entering an intensive period. This study is an important milestone that will bring us closer to the launch of a whole new generation of potency drugs," says Dicot Pharma's CEO Elin Trampe.
About the phase 2a study
The purpose of the Phase 2a study is to evaluate the efficacy of LIB-01 in men with erectile dysfunction. The study is expected to include 140 participants and is being conducted at six clinics in Sweden (Uppsala, Stockholm, Gothenburg and Linköping), Denmark (Herlev) and the Netherlands (Groningen). Each person will participate in the study for eight weeks after dosing. The trial is double blind and placebo controlled. This means that neither the clinical staff administering the study drug, nor the participants, know which research subjects are receiving LIB-01 and which are receiving placebo. The clinical part of the study is expected to last until mid-2025. This will be followed by a statistical analysis before the results can be reported.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot Pharma is listed on Nasdaq First North and has approximately 7,600 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.
This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.
